

CLAIMS

- Sub B3
1. A method of treating nerve damage comprising administering to a subject in need thereof an effective non-toxic amount of an MGF (mechano-growth factor) Insulin-like Growth Factor I (IGF-I) isoform comprising amino acid sequences encoded by nucleic acid sequences of IGF-I exons 4, 5 and 6 in the reading frame of MGF and having the ability to reduce motoneurone loss by 20% or greater in response to nerve avulsion, by localisation of said MGF at the site of said damage.
 2. A method of claim 1 wherein said nerve damage is to a nerve of the peripheral nervous system (PNS).
 3. A method of claim 1 wherein said MGF is localised at said site of the damage by means of a conduit placed around the nerve at said site of said damage.
 4. A method of claim 3 wherein said conduit comprises Poly-3-hydroxy-butyrate (PHB).
 5. A method of claim 1 wherein said damage comprises the severing of the nerve.
 6. A method of claim 2 wherein said treatment of said nerve damage is combined with a treatment that prevents or diminishes degeneration of the target organ which the damaged nerve innervates.
 7. A method of claim 6 wherein said target organ is a muscle and treatment of the muscle with MGF or a polynucleotide encoding MGF prevents or diminishes degeneration.

8. A method of claim 6 wherein treatment of the target organ with a polypeptide growth factor than than MGF prevents or diminishes degeneration.
9. A method of claim 1 wherein said MGF has the ability to reduce motoneurone loss by 50% or greater or 80% or greater in response to nerve avulsion
10. A method of claim 1 wherein said MGF is unglycosylated.
11. A method of claim 1 wherein said MGF has:
- (a) the sequence of Human MGF (SEQ ID NO. 2, Rat MGF (SEQ ID NO. 4) or Rabbit MGF (SEQ ID NO. 6);
 - (b) a sequence having 70% or greater homology to a sequence of (a);
 - (c) a sequence comprising the amino acids encoded wholly or partly by exons 4, 5 and 6 of human, rat or rabbit MGF DNA of SEQ ID NO. 1, 3 or 5, or a sequence having 70% or greater homology thereto; or
 - (d) a sequence encoded by a nucleic acid sequence capable of selectively hybridising to a sequence of (a), (b) or (c).
12. A method of claim 1, further comprising treatment with another neurologically active agent MGF is carried out in combination with said MGF.
13. A kit for the treatment of nerve damage comprising:
- (a) an MGF IGF-I isoform;
 - (b) a conduit adapted to be placed around a damaged nerve of the site of said damage;
 - (c) a further polypeptide growth factor which prevents or diminishes degeneration; and optionally
 - (d) another neurologically active agent.

SEQUENCE LISTING

<110> GOLDSPIK, GEOFFREY

<110> TERENCE, GIORGIO

<120> TREATMENT OF NEUROLOGICAL DISORDERS

<130> 117-351

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 518

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(330)

<400> 1

gga ccg gag acg ctc tgc ggg gct gag ctg gtg gat gct ctt cag ttc 48

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe

1 5 10 15

gtg tgt gga gac agg ggc ttt tat ttc aac aag ccc aca ggg tat ggc 96

Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly

20 25 30

tcc agc agt cgg agg gcg cct cag aca ggc atc gtg gat gag tgc tgc 144

Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys

35 40 45

50

55

60

Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp

65

70

75

80

Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Asn Thr

85

90

95

Lys Ser Gln Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys

100

105

110

aaaggacagggc caccgcagga ccctttgctc tgcacagtta cctgtaaaca ttggaataacc450

qtaaacaat 518

$\langle 211 \rangle$ 110

<212> PRT

<213> Homo sapiens

<400> 2

1

5

10

15

20

25

30

35

40

45

-42-

Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu

50

55

60

Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp

65

70

75

80

Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Asn Thr

85

90

95

Lys Ser Gln Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys

100

105

110

<210> 3

<211> 539

<212> DNA

<213> Rat

<220>

<221> CDS

<222> (1)..(333)

<400> 3

gga cca gag acc ctt tgc ggg gct gag ctg gtg gac gct ctt cag ttc 48

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe

1

5

10

15

gtg tgt gga cca agg ggc ttt tac ttc aac aag ccc aca gtc tat ggc 96

Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly

20

25

30

tcc agc att cgg agg gca cca cag acg ggc att gtg gat gag tgt tgc 144

Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys

35

40

45

ttc cgg agc tgt gat ctg agg agg ctg gag atg tac tgt gtc cgc tgc 192

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
1 5 10 15
Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
20 25 30
Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
35 40 45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys

N.82201 US GCW AB nw Specification as filed

-45-

50	55	60	
aag ccg gca aag gca gcc cgc tcc gtc cgt gcc cag cgc cac acc gac	240		
Lys Pro Ala Lys Ala Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp			
65	70	75	80
atg ccc aag act cag aag tat cag cct cca tct acc aac aag aaa atg	288		
Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Lys Met			
85	90	95	
aag tct cag agg aga agg aaa gga agt aca ttt gaa gaa cac aag	333		
Lys Ser Gln Arg Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys			
100	105	110	
tagagggagt gcaggaaaca agaactacag gatgtaggaa gacccttctg aggagtgaag	393		
aaggacaggc caccgcagga ccctttgctc tgcacagtta cctgtaaaca ttggaataacc	453		
ggccaaaaaa taagtttgat cacatttcaa agatggcatt tcccccaatg aaatacacaa	513		
gtaaacattc	523		

<210> 6

<211> 111

<212> PRT

<213> RABBIT

<400> 6

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
1 5 10 15
Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
20 25 30
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
35 40 45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
50 55 60

Lys Pro Ala Lys Ala Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
65 70 75 80
Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Lys Met
85 90 95
Lys Ser Gln Arg Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys
100 105 110

<210> 7

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: translation
initiation sequence

<400> 7

gccaccatgg

10

<210> 8

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: translation
initiation sequence

<400> 8

10

<211> 316

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(315)

<400> 9

gga ccg gag acg ctc tgc ggg gct gag ctg gtg gat gct ctt cag ttc 48

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe

1 5 10 15

gtg tgt gga gac agg ggc ~~ttt~~ tat ttc aac aag ccc aca ggg tat ggc 96

Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly

20 25 30

tcc agc agt cgg agg gcg cct cag/aca ggc atc gtg gat gag tgc tgc 144

Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys

35 40 45

ttc cgg agc tgt gat cta agg agg ctg gag atg tat tgc gca ccc ctc 192

Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu

50 55 \ 60

aag cct gcc aag tca gct cgc tct gtc cgt gcc cag cgc cac acc gac 240

Lys Pro Ala Lys Ser Ala Arg Ser Val Arg ~~Ala~~ Gln Arg His Thr Asp

65 70 75 80

atg ccc aag acc cag aag gaa gta cat ttg aag ~~aac~~ gca agt aga ggg 288

Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Ala Ser Arg Gly

[illegible]

Sub
at
cont

85 90 95 317
agt gca gga aac aag aac tac agg atg ag
Ser Ala Gly Asn Lys Asn Tyr Arg Met
100 105

<210> 10

<211> 105

<212> PRT

<213> Homo sapiens

<400> 10

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
1 5 10 15
Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
20 25 30
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
35 40 45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
50 55 60
Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
65 70 75 80
Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Ala Ser Arg Gly
85 90 95
Ser Ala Gly Asn Lys Asn Tyr Arg Met
100 105

<210> 11

<211> 487

<212> DNA

<213> Rat

<220>

<221> CDS

<222> (1)..(315)

<400> 11

gga cca gag acc ctt tgc ggg gct gag ctg gtg gac gct ctt cag ttc 48
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
1 5 10 15
gtg tgt gga cca agg ggc ttt tac ttc aac aag ccc aca gtc tat ggc 96
Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
20 25 30
tcc agc att cgg agg gca cca cag acg ggc att gtg gat gag tgt tgc 144
Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
35 40 45
ttc cgg agc tgt gat ctg agg agg ctg gag atg tac tgt gtc cgc tgc 192
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
50 55 60
aag cct aca aag tca gct cgt tcc atc cgg gcc cag cgc cac act gac 240
Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
65 70 75 80
atg ccc aag act cag aag gaa gta cac ttg aag aac aca agt aga gga 288
Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
85 90 95
agt gca gga aac aag acc tac aga atg taggaggagc ctcccagagga 335
Ser Ala Gly Asn Lys Thr Tyr Arg Met
100 105
acagaaaatg ccacgtcacc gcaagatcct ttgctgcttg agcaacctgc aaaacatcgg395

aacacdtgcc aaatatcaat aatgagtica atatcatttc agagatgggc atttcctca455
atgaaataca caagtaaaca ttcccgaat tc 487

<210> 12

<211> 105

<212> PRT

<213> Rat

<400> 12

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
1 5 10 15
Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
20 25 30
Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
35 40 45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
50 55 60
Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
65 70 75 80
Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
85 90 95
Ser Ala Gly Asn Lys Thr Tyr Arg Met
100 105

<210> 13

<211> 471

<212> DNA

<213> Rabbit

~~<222>~~ (1) .. (315)

N.82201 US GCW AB mw Specification as filed

<210> 14
<211> 105
<212> PRT
<213> Rabbit

<400> 14

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
1 5 10 15
Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
20 25 30
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
35 40 45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
50 55 60
Lys Pro Ala Lys Ala Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
65 70 75 80
Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
85 90 95
Ser Ala Gly Asn Lys Asn Tyr Arg Met
100 105